A Study of ARRY-334543 in Patients With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: DRUG: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer